Navigation Links
MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
Date:2/11/2009

VALENCIA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 fourth quarter financial results on Tuesday, February 17, 2009.

Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other Company developments at 4:00 p.m. ET on Tuesday, February 17, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the internet may do so by visiting the Company's website at http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (800) 756-2759 or (402) 998-0791.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
4. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
5. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
6. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
7. MannKind to Present at the UBS Global Life Sciences Conference
8. MannKind Corporation Reports Second Quarter Financial Results
9. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
10. MannKind to Present at Upcoming Conferences
11. MannKind Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... ... ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview with ... Tide". Dr. Harman and Dr. Riordan met in 2003 and have remained in contact ... stem cell therapy and a fast friendship was formed. , Dr. Harman has been a ...
(Date:9/19/2017)... California (PRWEB) , ... September 19, 2017 , ... ... biology technologies, today announced a partnership with Cytena GmbH to launch the CloneSelect™ ... and real-time image analysis to isolate single cells and provide visual documentation of ...
(Date:9/18/2017)... , Sept. 18, 2017   Montrium , a growing leader ... exciting new partnership with a groundbreaking non-profit research organization, Multidisciplinary ... ... psychotherapy studies for PTSD ... recently granted Breakthrough Therapy Designation to MDMA for the treatment of ...
(Date:9/14/2017)... London UK (PRWEB) , ... September 14, 2017 ... ... the most innovative minds in pharma and biotech at the third annual DrugDev ... collaborative conference that brings together the world’s most progressive clinical research leaders for ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):